WHITE PAPER

ADVANCED HEART FAILURE MONITORING IN CARDIAC RHYTHM MANAGEMENT DEVICES

Infosys
Navigate your next

Heart failure is a serious medical condition affecting more than 64 million people globally. It is a leading cause of hospitalization, reduced quality of life, and rising healthcare costs. Although therapeutic interventions have improved significantly, detecting worsening symptoms at an early stage remains a major challenge. This article examines how conventional Cardiac Rhythm Management (CRM) devices, originally used to treat arrhythmias, are evolving into continuous AI-based health monitoring systems that enable proactive heart failure management. Contemporary CRM devices incorporate multisensor technology to continuously monitor vital physiological parameters, including fluid accumulation, heart sounds, respiratory rate, heart rate variability, atrial fibrillation burden, and physical activity levels. These devices can analyze these signals and identify early signs of decompensation before patients experience symptoms, enabling timely clinical intervention. The article compares two leading rule-based heart failure monitoring platforms: HeartLogic (Boston Scientific) and TriageHF (Medtronic). These platforms are integrated into remote monitoring workflows, allowing automated data uploads, real-time analysis, and physician review. The data collected also lays the foundation for future AI integration. The article further highlights industry and regulatory considerations such as HIPAA and GDPR compliance, system integration, real-world evidence requirements, and clinician trust in automated systems. The paper concludes that the shift from reactive to proactive care in CRM technologies is transforming heart failure management by enabling earlier intervention, improving outcomes, and increasing healthcare system efficiency.

Introduction

Heart failure (HF) is a condition in which the heart cannot pump enough blood to meet the body's needs. It is a growing global health concern, affecting more than 64 million people and serving as a major cause of hospital admissions, reduced quality of life, and increased healthcare costs. Despite advances in medical treatment, early identification of worsening symptoms remains a challenge in preventing emergency events. In recent years, technological advances in implantable cardiac devices have added a new dimension to patient care. Traditionally, these devices were used to treat abnormal heart rhythms; today, they also support continuous monitoring of the patient's condition and provide early alerts. This white paper explains how these advanced devices work and why their evolving role is important not only for clinicians, but also for patients, caregivers, healthcare systems, and the broader public.

Background

In the past, heart failure management relied largely on how patients felt and what physicians observed during routine visits. Unfortunately, the body often compensates silently until the disease has progressed significantly. As a result, conventional approaches often miss the window for early intervention. This is where Cardiac Rhythm Management (CRM) devices play an important role. Initially designed to correct rhythm abnormalities or support weak heartbeats, CRM devices now function as internal health monitors. They continuously gather data from within the body, providing a clearer and more continuous picture of how the heart and lungs are functioning and, in many cases, identifying problems before the patient notices any symptoms.

Multi-sensor monitoring in CRM devices

CRM devices now include several built-in sensors that collect health data. This is like having a tiny, specialized medical lab inside the chest, working around the clock. These sensors monitor the following:

a. Thoracic impedance

This measures the resistance of the chest region to electrical signals. When fluid accumulates in the lungs, which is a sign of heart failure, the impedance decreases. This change can be detected to warn of potential problems days before symptoms appear.

b. Heart sounds (S1, S3)

These sensors can detect abnormal patterns by sensing the vibrations produced by the heart. For example, an S3 sound may indicate that the heart is under stress and having difficulty pumping effectively.

c. Respiratory rate and tidal volume

Changes in breathing patterns, such as rapid, shallow breathing, can indicate that the heart is not delivering enough oxygenated blood and that the body is compensating.

Fig. 1 Anatomy of a CRM Device with Sensor Placement



d. Heart rate variability (HRV)

This is the time variation between beats. Reduced HRV can indicate that the nervous system of the body is stressed, and it can be an early indicator of deteriorating heart failure.

e. Atrial fibrillation (AF) burden

If the upper chambers of the heart beat too rapidly or irregularly, blood flow may be disrupted and heart failure symptoms can worsen. Monitoring systems track how frequently these irregular rhythms occur and how long they last.

f. Levels of physical activity

Monitors measure movement using integrated accelerometers. If a patient's level of activity decreases drastically, it can be an indicator of fatigue, shortness of breath, or other symptoms associated with heart failure.

Together, these measurements provide early warning signals to healthcare teams and help them act before problems escalate.

Fig. 2 Signal Flow and Risk Score Generation



Heartlogic and TriageHF: comparative overview

Table I
Difference between HeartLogic (Boston Scientific) and TriageHF (Medtronic)

Feature	HeartLogic (Boston Scientific)	TriageHF (Medtronic)
Physiological Signals	S1, S3, respiration, thoracic impedance, activity, night HR	Thoracic impedance, AF burden, HRV, activity, shocks
Algorithm Type	Composite Index	Risk Score
Predictive Capability	Median 34-day advance warning	Similar early warning period
Remote Monitoring	LATITUDE NXT	CareLink
AI-Based	No (rule-based analytics)	No (rule-based analytics)

HeartLogic and TriageHF are two technologies that use data from CRM devices to predict when a patient may experience worsening heart failure. HeartLogic combines multiple sensor inputs to generate a single index score that rises with increasing risk. TriageHF provides a simpler traffic-light-style rating of low, medium, or high risk. These scores are reviewed by healthcare professionals to support clinical decision-making. Although neither system currently uses artificial intelligence (AI), both represent a significant shift from reactive to proactive care.

Clinical workflow and utility

For someone unfamiliar with clinical workflows, a CRM device can be thought of as a health-monitoring assistant that reports to a physician in real time. This is how it works:

a. Data reporting from within the body

The implanted device continuously collects information about the patient's condition without requiring the patient to do anything.

b. Transmission of data to safe platforms

The data is transmitted to cloud-based platforms that physicians can access through secure dashboards.

c. Computerized analysis of medical data

In-built software analyzes the incoming data and provides a risk score or warning flag.

d. Physician review and response

Medical teams are notified when something unusual is detected, enabling them to contact the patient, adjust medications, or arrange an early visit.

In many cases, this system enables issues to be detected before symptoms appear, potentially reducing emergency room visits and hospitalizations.

Fig. 3 Timeline Comparison – Clinical Symptoms vs. Device Alert





RELEVANCE TO ARTIFICIAL INTELLIGENCE

Artificial intelligence (AI) may sound futuristic, but it is becoming increasingly relevant in healthcare. Although HeartLogic and TriageHF do not use AI yet, the data they collect could soon be used by AI models.

This is how AI might improve these platforms:

a. Learning from patterns
AI can analyze hundreds of thousands of patient histories to identify which signals tend to precede heart failure episodes.

b. More intelligent grouping of patients
AI can uncover hidden patterns and classify patients in more meaningful ways, helping clinicians tailor treatments more effectively.

c. Tailored treatment plans
In the long term, AI could help determine which treatments are most effective for individual patients based on how similar patients have responded.

d. Detecting distinctive warning signs
AI may detect subtle changes in a person's health data that conventional systems might overlook.

Challenges to Address: How can AI be made accessible to physicians and patients? How can private health information be protected? How can AI be made effective for diverse patient populations? These are some of the major questions that companies and regulators must address.

Fig. 4 AI Integration Roadmap for CRM Devices





Industry landscape and regulatory considerations

For the medical device industry to bring these innovations to market, several factors must be addressed:

a. Privacy and data protection
Devices must follow laws like HIPAA (US) and GDPR (EU).

b. Proving the benefits
Real-world evidence is crucial to gaining approval.

c. Compatibility with hospital systems
Integration with existing healthcare infrastructure is necessary.

d. Ongoing safety checks
Continuous evaluation helps ensure effectiveness.

e. Clarity in AI models
Explainability and clinician trust are vital for adoption.

FUTURE DIRECTIONS AND INDUSTRY IMPLICATIONS

The next generation of CRM technology will most likely include:

- Miniaturization and longer battery life
- Enhanced sensors for parameters such as blood pressure and oxygen saturation
- Compatibility with consumer wearables
- AI-enhanced analytics for real-time care decisions
- Patient-friendly apps for enhanced engagement and compliance

CONCLUSION

Advanced CRM devices are transforming heart failure care. Through continuous monitoring and early notifications to care teams, these devices can help prevent life-threatening events. As AI becomes more integrated, the shift from crisis management to proactive care will continue to accelerate. The result is a more effective, personalized, and promising future for patients and for the healthcare systems that support them.

References

1. P. Ponikowski et al., "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure," European Heart Journal, vol. 37, no. 27, pp. 2129–2200, Jul. 2016. doi: 10.1093/eurheartj/ehw128.

2. J. P. Boehmer et al., "A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE Study," Journal of the American College of Cardiology, vol. 69, no. 24, pp. 2747–2758, Jun. 2017. doi: 10.1016/j.jacc.2017.04.001.

3. Medtronic, "TriageHF™ Clinical Overview," 2023. [Online]. Available: https://www.medtronic.com/us-en/healthcare-professionals/products/cardiac-rhythm/heart-failure/triagehf-technology.html

4. B. Ziaeian and G. C. Fonarow, "Epidemiology and aetiology of heart failure," Nature Reviews Cardiology, vol. 13, no. 6, pp. 368–378, Jun. 2016. doi: 10.1038/nrcardio.2016.25.

5. J. Stehlik et al., "Remote Monitoring of Patients With Heart Failure: An Overview of Current Technology and Future Trends," Cardiology Clinics, vol. 37, no. 4, pp. 509–521, Nov. 2019. doi: 10.1016/j.ccl.2019.07.005.

Authors

Manish Snehi
Senior Technology Architect, Infosys

Ankita Khanna
Digital Solution Specialist, Infosys

For more information, contact askus@infosys.com

Infosys
Navigate your next

Infosys.com | NYSE: INFY

Stay Connected